Articles tagged with Sarcoma
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.
Researchers develop new approach to prevent chemotherapy-related leukemia by analyzing blood samples from four clinical trials, showing a 26-36% reduction in blood cell growth with mutated TP53 gene. They also discover that monoclonal antibodies can turn neutrophils into cancer killers and induce tumor eradication in preclinical models.
The National Comprehensive Cancer Network has published new guidelines for Pediatric Soft Tissue Sarcomas, highlighting the unique characteristics of this childhood cancer. The guidelines focus on rhabdomyosarcoma (RMS), a subtype with varying genetic changes that influence treatment outcomes.
Researchers at Penn Vet have shown that trained dogs can identify the odor of hemangiosarcoma, a malignant cancer of blood vessel cells, with an accuracy rate of 70%. Early detection could lead to better outcomes, including prevention of disease spread and earlier removal of the spleen or initiation of chemotherapy.
A new study from Fox Chase Cancer Center confirms that preoperative radiation therapy does not reduce surgical complexity in patients with retroperitoneal sarcoma. The research suggests that most patients benefit from proceeding directly to surgery, as skipping radiation has no significant impact on tumor size or surgical outcomes.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
A new Curtin University study reveals that people diagnosed with sarcoma, a rare and complex cancer, are being left without the resources they urgently need. The research found that many online resources significantly lacked emotional support, practical guidance, age-specific information, and dedicated resources for caregivers.
Researchers identified a targeted drug that blocks a specific genetic pathway to reverse tumor-driving cellular interactions, potentially restoring DNA function and benefiting patients with synovial sarcoma. The study's findings endorse a promising strategy to improve outcomes for this rare but deadly cancer.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
A new targeted radiation approach has achieved a near-complete response in three patients with solitary fibrous tumor (SFT), a rare and aggressive form of cancer. The therapy significantly reduced cancer activity and provided symptom relief, highlighting its potential as a treatment option.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that using a drug as a blocker to outcompete the SUMO2 protein may be a winning strategy against synovial sarcoma. This approach aims to reverse aberrant epigenetic rewiring driven by the SS18::SSX fusion oncoproteins and impair sarcomagenesis.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
Researchers at U. Iowa identify a specific metabolic pathway that fuels tumor growth in MPNST, providing a promising new target for treatment. By blocking this pathway, tumors grow more slowly and are more vulnerable to chemotherapy.
Researchers at UCLA have successfully created a continuous supply of functional T cells using genetically engineered stem cells. This breakthrough could lead to longer-lasting protection against cancer and potentially treat other diseases such as HIV or autoimmune disorders.
Researchers highlight microRNAs as crucial biomarkers for diagnosing and monitoring soft tissue sarcomas, with potential for precision medicine. MicroRNAs could help distinguish between tumor types and guide treatment decisions.
Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...
Researchers at Fox Chase Cancer Center found that fragmented care does not negatively impact survival outcomes for retroperitoneal sarcoma patients. Despite longer travel distances and delays between diagnosis and treatment, patients receiving nonfragmented care had equivalent overall survival rates as those with non-fragmented care.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at Osaka Metropolitan University found that plasma-activated medium reduces synovial sarcoma tumor growth in human cells and mice, with no obvious side effects. The treatment was verified through in vitro and in vivo tests, offering a new potential treatment option for this rare form of cancer.
Researchers have developed an AI-driven model that can accurately diagnose various subtypes of pediatric sarcoma using only routine pathology images. The model correctly distinguished between nine sarcoma subtypes, demonstrating its potential to provide quick and accurate cancer diagnoses in under-resourced settings.
NGR Oncology has created a new Sarcoma Subcommittee to improve outcomes for adults with cancer, focusing on building a robust program, collaborating with the Children's Oncology Group, and promoting sarcoma research. The subcommittee is led by Chair Dian Wang, MD, PhD, and Vice-Chairs William Tseng, MD, and Brian A Van Tine, MD, PhD.
The ESMO Sarcoma and Rare Cancers Congress 2025 will bring together experts to present and discuss developments in diagnosing and treating rare solid tumours. The event will focus on immunotherapy, global challenges, and opportunities for international collaboration.
A team led by Prof. Woo Young Jang developed a novel fluorescent probe to visualize cancer stem cells in complex samples, offering a new direction for cancer diagnostic imaging. This technology has significant implications for diagnosing and monitoring sarcomas.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Two comprehensive datasets from the Gabriella Miller Kids First Pediatric Research Program explore childhood cancers and congenital disorders. The new datasets aim to identify genetic causes and links between these diseases in children, ultimately supporting the development of improved treatments.
Researchers found lower incidence rates of soft tissue sarcomas among young U.S. active-duty military servicemen compared to the general population, likely due to better health and early detection within the military health system. In contrast, middle-aged servicemen showed higher rates, possibly due to greater cumulative exposure to t...
Ewing sarcoma, a rare childhood cancer, is made more aggressive by the absence of STAG2 protein. This discovery provides potential biomarkers and therapeutic targets for treatment.
A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers report a case of undifferentiated spindle cell sarcoma with primary insensitivity to standard chemotherapy, but a pronounced response to BRAF/MEK inhibitors at recurrence. The tumor was found to be BRAF exon 15 double-mutated: c.1799T>A p.V600E and c.1819T>A p.S607T.
Researchers found that FAP-targeted radioligand therapy controlled disease progression in nearly half of patients with advanced sarcoma, and was well-tolerated without critical organ radiation dose levels being reached. The study's results indicate a promising approach for this patient group with limited treatment options.
A University of California - Riverside study finds that medium-sized dogs have a higher risk of developing cancer than larger or smaller breeds. The multistage model of cancer acquisition supports this finding, suggesting that size is a major risk factor for cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a mouse model of Kaposi sarcoma, which could facilitate the development of new drugs to treat the disease. The model provides a better understanding of angiogenesis and its potential targets for therapy.
Researchers used machine learning tools to map distinct cellular configurations in soft tissue sarcomas, identifying correlations between cell types and clinical outcomes. The analysis uncovered three multicellular communities that correlated with patients' prognoses, potentially informing treatment decisions.
A team of researchers from Kyoto University has developed a microfluidic co-culture vasculature chip that mimics the microenvironment of alveolar soft part sarcoma (ASPS), a rare cancer. The chip enables scientists to study cell-to-cell interactions and angiogenic mechanisms, which may lead to new strategies for treating ASPS patients.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
A Phase II trial found that neoadjuvant immunotherapy significantly reduced residual tumor and improved overall survival for patients with undifferentiated pleomorphic sarcoma, with 90% having less than 15% viable tumor cells remaining. The treatment approach is a promising option for patients with limited systemic therapy options.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.
A new clinical trial has shown promising results for nirogacestat, a targeted drug that blocks the Notch protein. In the Phase 3 trial, 41% of patients' tumors significantly shrank after taking nirogacestat, with no growth in over 75%. The most common side effects were fatigue, gastrointestinal problems, and skin rashes.
Researchers have identified a new method to predict which sarcoma patients will benefit from a potential new treatment. By inhibiting the plk1 gene, they were able to target and slow down the growth of sarcoma cells. This breakthrough could lead to improved treatment options for sickest sarcoma patients in 5-10 years.
A systematic review and meta-analysis found that MRI-based surveillance after surgical treatment can detect clinically occult local recurrences, potentially improving patient outcomes. The study included 19 studies and showed a significant association between high-intensity surveillance and the detection of local recurrences.
Eleni Tomazou's project aims to create in vitro and in vivo models of pediatric sarcomas to accelerate drug discovery and precision medicine. Her work could lead to a significant impact on the treatment of these deadly cancers.
Scientists at Cold Spring Harbor Laboratory have found a way to reprogram cells causing Ewing sarcoma to behave like normal connective tissue cells. By blocking the protein ETV6, cancer cells can be forced to take on a new identity and grow less aggressively.
Researchers have created a genetic map to identify important genes causing sarcoma, a common childhood cancer. The study found that one in 14 individuals with sarcoma carries a clinically significant gene, offering hope for earlier diagnosis and treatment.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
In a Phase I clinical trial, afami-cel achieved an objective response rate of 44% in patients with synovial sarcoma and 24% across all cancer types. The therapy demonstrated manageable toxicity and early activity in other cancer types, suggesting potential for solid tumors.
Scientists used AI-driven PandaOmics platform to analyze gene expression datasets from DNA repair diseases, identifying biomarkers associated with treatment response. The study focused on genes that stratify cancer patients by survival outcomes, providing potential targets for personalized therapies.
Researchers have identified two subgroups of Ewing sarcoma that respond differently to targeted drug therapy, with the first group responding to Linsitinib and AZD1775 treatment. The study suggests that repeated biopsies may be needed over time to determine the best course of treatment for each patient.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers found a significant increase in Kaposi's sarcoma incidence among young Black men in the South, with rates jumping by 3.3% per year. The study suggests that HIV infection and social determinants like poverty and lack of access to medical care contribute to this disparity.
Patients with non-metastatic soft tissue sarcoma can safely receive hypofractionated treatment over three weeks instead of five, achieving similar tumor control and no increased risk of wound complications. The study found comparable rates of major wound complications between the two treatment courses.